BRPI0408439A - composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético - Google Patents

composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético

Info

Publication number
BRPI0408439A
BRPI0408439A BRPI0408439-0A BRPI0408439A BRPI0408439A BR PI0408439 A BRPI0408439 A BR PI0408439A BR PI0408439 A BRPI0408439 A BR PI0408439A BR PI0408439 A BRPI0408439 A BR PI0408439A
Authority
BR
Brazil
Prior art keywords
factor
treating
pharmaceutical composition
liquid pharmaceutical
factor vii
Prior art date
Application number
BRPI0408439-0A
Other languages
English (en)
Inventor
Michael Bech Jensen
Birthe Lykkegaard Hansen
Troels Kornfelt
Kirsten Kramer Jakobsen
Janus Krarup
Egon Persson
Anders Klarskov Petersen
Andrew Neil Bowler
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of BRPI0408439A publication Critical patent/BRPI0408439A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Wrappers (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA LìQUIDA AQUOSA, MéTODO PARA PREPARAR E USO DA MESMA, MéTODO PARA TRATAR UMA SìNDROME RESPONSIVA AO FATOR VII, E, RECIPIENTE HERMéTICO". A invenção diz respeito a uma composição farmacêutica líquida aquosa que compreende um polipeptídeo do Fator VII (por exemplo, Fator VIIa de humano) e agente de tamponamento; em que a razão molar de íons cálcio não complexados (Ca¬ 2+¬) para o polipeptídeo do Fator VII é inferior a 0,5. A composição pode ainda compreender um agente de estabilização (por exemplo, íons cobre ou magnésio, benzamidina ou guanidina), um tensoativo não iónico, um agente modificador de tonicidade, um antioxidante e um conservante. A composição é útil para tratar uma síndrome responsiva ao Fator VII, tal como distúrbios de hemorragia, incluindo aqueles causados pelas deficiências do Fator de coagulação (por exemplo, hemofilia A, hemofilia B, deficiência do Fator XI de coagulação, deficiência do Fator VII de coagulação); pela trombocitopenia ou doença de von Willebrand ou pelos inibidores do fator de coagulação e hemorragia intracerebral ou hemorragia excessiva de qualquer causa. As preparações também podem ser administradas aos pacientes em associação com cirurgia ou outro trauma ou aos pacientes que recebam terapia anticoagulante.
BRPI0408439-0A 2003-03-18 2004-03-18 composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético BRPI0408439A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200300413 2003-03-18
DKPA200300788 2003-05-23
DKPA200300959 2003-06-25
DKPA200300995 2003-07-01
DKPA200301161 2003-08-14
PCT/DK2004/000181 WO2004082708A2 (en) 2003-03-18 2004-03-18 Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides

Publications (1)

Publication Number Publication Date
BRPI0408439A true BRPI0408439A (pt) 2006-04-04

Family

ID=36074830

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408439-0A BRPI0408439A (pt) 2003-03-18 2004-03-18 composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético

Country Status (10)

Country Link
US (1) US20060063714A1 (pt)
EP (1) EP1605968A2 (pt)
JP (1) JP2006524195A (pt)
KR (1) KR20050110682A (pt)
AU (1) AU2004222625A1 (pt)
BR (1) BRPI0408439A (pt)
CA (1) CA2518327A1 (pt)
MX (1) MXPA05009914A (pt)
RU (1) RU2005132164A (pt)
WO (1) WO2004082708A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2325653T3 (es) 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
BRPI0409936A (pt) * 2003-05-23 2006-04-25 Novo Nordisk Healthcare Ag uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
WO2005016365A2 (en) 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
ES2676644T3 (es) * 2003-12-19 2018-07-23 Novo Nordisk Health Care Ag Composiciones estabilizadas de polipéptidos de factor VII
EP1745141B2 (en) 2004-05-04 2019-09-25 Novo Nordisk Health Care AG O-linked glycoforms of faktor vii and method to manufacture them
WO2006089952A1 (en) * 2005-02-24 2006-08-31 Novo Nordisk Health Care Ag Amidino-compounds por stabilizing factor vii polypeptide formulations
WO2006089953A1 (en) * 2005-02-24 2006-08-31 Novo Nordisk Health Care Ag Compounds for stabilizing factor vii polypeptide formulations
US20090041747A1 (en) * 2005-02-24 2009-02-12 Novo Nordisk Health Care Ag Compounds for Stabilizing Factor VII Polypeptide Formulations
BRPI0608170A2 (pt) * 2005-04-28 2010-11-09 Novo Nordisk Healthcare Ag recipiente fechado contendo uma composição de um polipeptìdeo do fator vii ativado, processo para a preparação de um recipiente fechado contendo um polipeptìdeo do fator vii ativado, kit, e, método para a preparação de uma composição farmacêutica
WO2007022784A2 (en) * 2005-08-26 2007-03-01 Maxygen Holdings Ltd. Liquid factor vii composition
JP2007244606A (ja) * 2006-03-15 2007-09-27 Hisamitsu Pharmaceut Co Inc シリンジ、及びシリンジの製造方法
JP4829828B2 (ja) 2007-03-28 2011-12-07 シスメックス株式会社 血液凝固測定用試薬及び組織因子安定化方法
WO2008135500A1 (en) 2007-05-02 2008-11-13 Novo Nordisk Health Care Ag High concentration factor vii polypeptide formulations comprising an aromatic preservative and an antioxidant
WO2009002521A2 (en) 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009027478A2 (en) * 2007-08-29 2009-03-05 Novo Nordisk Health Care Ag A method of removing preservatives from a liquid pharmaceutical preparation
AU2009248885B2 (en) * 2008-05-23 2015-02-05 Hospira, Inc. Packaged iron sucrose products
JP2011520999A (ja) * 2008-05-23 2011-07-21 ノボ ノルディスク ヘルス ケア アーゲー 高濃度の芳香族保存料を有するペグ官能化セリンプロテアーゼの製剤
JP2012520098A (ja) * 2009-03-30 2012-09-06 エフ．ホフマン−ラ ロシュ アーゲー ガラスの曇りを防ぐための方法
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
PL3446682T3 (pl) 2016-04-22 2021-12-13 Rohto Pharmaceutical Co., Ltd. Kompozycja okulistyczna
CN109069421B (zh) * 2016-04-22 2021-10-12 乐敦制药株式会社 眼科组合物
DE102018104163A1 (de) * 2018-02-23 2019-08-29 Schott Ag Glasfläschchen mit geringer Migrationslast

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US115590A (en) * 1871-06-06 Lfxlproxeixie
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4956386A (en) * 1980-04-25 1990-09-11 Gist-Brocades N.V. Pharmaceutical compositions and process for their preparation
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
CA2074839C (en) * 1990-01-29 2000-11-14 Kathleen L. Berkner Modified factor vii anticoagulant proteins
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
WO1995003332A1 (en) * 1993-07-23 1995-02-02 Baxter International Inc. Activated human factor viii and method of preparation
US6277828B1 (en) * 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US5649959A (en) * 1995-02-10 1997-07-22 Sherwood Medical Company Assembly for sealing a puncture in a vessel
US5993795A (en) * 1995-11-09 1999-11-30 Takemoto Yushi Kabushiki Kaisha Protein composition derived from sesame seed and use thereof
US6320029B1 (en) * 1996-11-29 2001-11-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5830852A (en) * 1995-12-19 1998-11-03 Cobra Therapeutics, Ltd. Compositions for insulin-receptor mediated nucleic acid delivery
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6461610B1 (en) * 1997-07-18 2002-10-08 Novo Nordisk A/S Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
PT2193809E (pt) * 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US20010031721A1 (en) * 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
JP4674021B2 (ja) * 1999-07-13 2011-04-20 ビオヴィトルム・アクチボラゲット（プブリクト） 安定第ｖｉｉｉ因子組成物
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
ATE389414T1 (de) * 1999-09-08 2008-04-15 Chugai Pharmaceutical Co Ltd Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
PL204285B1 (pl) * 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
AU9165201A (en) * 2000-10-02 2002-04-15 Novo Nordisk As Factor vii glycoforms
WO2002038162A1 (en) * 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
GB0117879D0 (en) * 2001-07-21 2001-09-12 Common Services Agency Storage of liquid compositions
US6858587B2 (en) * 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
WO2003039585A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
ES2325653T3 (es) * 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
JP2005530682A (ja) * 2001-12-21 2005-10-13 ノボ　ノルディスク　アクティーゼルスカブ 修飾第ｖｉｉ因子ポリペプチドの液体組成物
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII

Also Published As

Publication number Publication date
JP2006524195A (ja) 2006-10-26
RU2005132164A (ru) 2006-06-10
US20060063714A1 (en) 2006-03-23
CA2518327A1 (en) 2004-09-30
MXPA05009914A (es) 2006-01-09
WO2004082708A3 (en) 2005-03-17
KR20050110682A (ko) 2005-11-23
WO2004082708A2 (en) 2004-09-30
EP1605968A2 (en) 2005-12-21
AU2004222625A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
BRPI0408439A (pt) composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
BR0109548A (pt) Composição de manteiga de noz com baixo teor de gordura com fibra e proteìna elevada
BR0110659A (pt) Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo
BRPI0412241A (pt) formulação para medicamentos de proteìna sem adição de albumina de soro humano (hsa)
Kemper et al. Frostbite of both first digits of the foot treated with delayed hyperbaric oxygen: a case report and review of literature
BRPI9906372B8 (pt) composição farmaceutica aquosa para aplicação na mucosa
BRPI0414215A (pt) tienopirazóis
JP2005516024A5 (pt)
JPH04211019A (ja) 創傷治癒促進のためのトロンボスポンデインの使用
Levy Hemostatic agents.
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
BR0104305A (pt) Aparelhos e métodos para cirurgia cardìaca
BR0211256A (pt) Composição farmacêutica, kit, usos de um polipeptìdeo relacionado ao fator vii ou fator vii em combinação com um polipeptìdeo relacionado ao fator xi ou fator xi e de uma composição, e, métodos para tratar de episódios de hemorragia em um paciente, para reduzir o tempo de coagulação em um paciente, para intensificar a hemostasia em um paciente, para prolongar o tempo de lise do coágulo e para aumentar a resistência do coágulo em um paciente
BRPI0416461A (pt) método para o tratamento de episódios de sangramento, formulação farmacêutica, e, uso de um polipeptìdeo fxi
ATE518533T1 (de) Pharmazeutische zusammensetzung, die einen spezifischen aminopeptidase-a inhibitor enthält, insbesondere ec33, zur senkung des blutdrucks
Shetty Effectiveness of intravenous haemocoagulase on haemorrhage control in bi-maxillary orthognathic surgery—a prospective, randomised, controlled, double-blind study
CN105617448A (zh) 纤维蛋白复合止血材料及其制备方法
ATE446768T1 (de) Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
HUE009867T2 (pt)
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
US20080233176A1 (en) Haemostatic composition and method
BR0213953A (pt) Composição farmacêutica, kit de partes, uso de fator vii ou um polipeptìdeo relacionado com fator vii em combinação com um fator v ou um polipeptìdeo relacionado com fator v, uso de uma composição, métodos para tratar episódios de sangramento em um sujeito, para reduzir o tempo de coagulação, para intensificar hemóstase, para prolongar o tempo de lise de coágulos em um sujeito, e para incrementar a resistência do coágulo em um sujeito, kit contendo um tratamento para episódios de sangramento
BR9917605A (pt) Composição substituta de plasma
ATE433743T1 (de) Ternäre eutektische gemische von lokalanaesthetika

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.